Study identifies promising drug target in certain breast and ovarian cancers
The Food and Drug Administration's recent approval of the drug olaparib for ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2 came as welcome news to the thousands of women now eligible to receive ...
Feb 16, 2015
0
59